Literature DB >> 12434471

Zoledronic acid.

Angie Osborne1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12434471     DOI： 10.1188/02.CJON.365-366

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN： 1092-1095            Impact factor:   1.027


× No keyword cloud information.
  4 in total

1.  Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient's Quality of Life: A Single-Center, 10-Year Experience from Southern Italy.

Authors:  Giacomo Oteri; Gianluca Trifirò; Matteo Peditto; Loredana Lo Presti; Ilaria Marcianò; Francesco Giorgianni; Janet Sultana; Antonia Marcianò
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

2.  Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.

Authors:  Xinmin Zhao; Xiaofeng Xu; Qunling Zhang; Zhen Jia; Si Sun; Jian Zhang; Biyun Wang; Zhonghua Wang; Xichun Hu
Journal:  BMC Cancer       Date:  2011-09-22       Impact factor: 4.430

3.  Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid.

Authors:  Toni Ibrahim; Laura Mercatali; Emanuele Sacanna; Anna Tesei; Silvia Carloni; Paola Ulivi; Chiara Liverani; Francesco Fabbri; Michele Zanoni; Wainer Zoli; Dino Amadori
Journal:  Cancer Cell Int       Date:  2012-11-22       Impact factor: 5.722

Review 4.  Dosing of zoledronic acid with its anti-tumor effects in breast cancer.

Authors:  Xinmin Zhao; Xichun Hu
Journal:  J Bone Oncol       Date:  2015-10-03       Impact factor: 4.072
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.